HLB Therapeutics Co.,Ltd. Logo

HLB Therapeutics Co.,Ltd.

Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.

115450 | KO

Overview

Corporate Details

ISIN(s):
KR7115450009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 정자일로 248, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's core focus is on its clinical pipeline, which includes RGN-259, a therapeutic candidate for ophthalmic conditions such as Neurotrophic Keratopathy and Dry Eye Disease, and OKN-007 for treating Glioblastoma Multiforme. In addition to its primary research and development activities, the company has diversified business areas that include vaccine distribution and cold chain logistics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-28 00:00
Share Issue/Capital Change
전환가액의조정
Korean 10.6 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.3 KB
2025-08-21 00:00
Share Issue/Capital Change
전환가액의조정
Korean 11.8 KB
2025-08-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 136.8 KB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 141.7 KB
2025-07-03 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-01 00:00
Share Issue/Capital Change
전환가액의조정
Korean 13.1 KB
2025-06-20 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 73.7 KB
2025-05-28 00:00
Share Issue/Capital Change
전환가액의조정 (제18회차)
Korean 10.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-05-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 119.0 KB
2025-05-21 00:00
Share Issue/Capital Change
전환가액의조정 (제17회차)
Korean 11.3 KB

Automate Your Workflow. Get a real-time feed of all HLB Therapeutics Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Therapeutics Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Therapeutics Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.